Amanda Ayers
Impact in
- Infectious Diseases top 1%
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- Neurology top 5%
- Long-Term Effects of COVID-19
Papers in
-
- SARS-CoV-2 and COVID-19 Research 5
- COVID-19 Clinical Research Studies 3
-
- interferon and immune responses 3
- Journals
- The Lancet (7 papers)Nature (4 papers)Human Genetics and Genomics Advances (1 paper)Kidney International Reports (1 paper)
- Partner nations
- United KingdomAustraliaIndonesia
In The Last Decade
Amanda Ayers
13 papers receiving 2.6k citations
Amanda Ayers's Hit Papers
Peers
Comparison fields: 5 of 115
- Infectious Diseases 1.4k
- Neurology 447
- Applied Microbiology and Biotechnology 50
- Internal Medicine 58
- Immunology 332
Countries citing papers authored by Amanda Ayers
This map shows the geographic impact of Amanda Ayers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amanda Ayers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amanda Ayers more than expected).
Fields of papers citing papers by Amanda Ayers
This network shows the impact of papers produced by Amanda Ayers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amanda Ayers. The network helps show where Amanda Ayers may publish in the future.
No co-authors to show.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Mapping the human genetic architecture of COVID-19 Hit paper breakdown → | 2021 | 641 |
| 2 | Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2021 | 403 |
| 3 | Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial Hit paper breakdown → | 2021 | 381 |
| 4 | Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2022 | 282 |
| 5 | Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis Hit paper breakdown → | 2022 | 230 |
| 6 | Whole-genome sequencing reveals host factors underlying critical COVID-19 Hit paper breakdown → | 2022 | 228 |
| 7 | Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2021 | 211 |
| 8 | GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19 Hit paper breakdown → | 2023 | 121 |
| 9 | 2023 | 83 | |
| 10 | 2023 | 56 | |
| 11 | 2024 | 52 | |
| 12 | 2024 | 8 | |
| 13 | 2024 | 5 |
About Amanda Ayers
Amanda Ayers is a scholar working on Infectious Diseases, Immunology, Genetics, Epidemiology and Cell Biology, having authored 13 papers that have together received 2.7k indexed citations. Recurring topics across this work include SARS-CoV-2 and COVID-19 Research (5 papers), COVID-19 Clinical Research Studies (3 papers), interferon and immune responses (3 papers), Liver Disease Diagnosis and Treatment (1 paper), Respiratory viral infections research (1 paper), Diabetes and associated disorders (1 paper), Genetic Associations and Epidemiology (1 paper) and Endoplasmic Reticulum Stress and Disease (1 paper). The work is most often cited by research in Infectious Diseases (1.4k citations), Neurology (447 citations), Applied Microbiology and Biotechnology (50 citations), Internal Medicine (58 citations) and Immunology (332 citations). Amanda Ayers has collaborated with scholars based in United Kingdom, Australia and Indonesia. Their work appears in journals such as The Lancet, Nature, Human Genetics and Genomics Advances and Kidney International Reports.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.